Ceftaroline: A comprehensive update

International Journal of Antimicrobial Agents

Volumn 37, Issue 5, 2011, Pages 389-395

  Kaushik, Darpan ^a   Rathi, Sudeep ^a   Jain, Ankit ^a  

^a Rajendra Institute of Technology and Sciences   (India)

Author keywords

Ceftaroline; Community associated pneumonia (CAP); Complicated skin and skin structure infections (cSSSIs); Meticillin resistant Staphylococcus aureus (MRSA); Penicillin binding proteins (PBPs)

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CYTOCHROME P450; NXL 104; PENICILLIN BINDING PROTEIN; PHOSPHATASE; UNCLASSIFIED DRUG; VANCOMYCIN;

AEROBIC BACTERIUM; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL ENDOCARDITIS; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; COMMUNITY ACQUIRED PNEUMONIA; CREATINE KINASE BLOOD LEVEL; CRYSTALLURIA; DEPHOSPHORYLATION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; INJECTION SITE THROMBOSIS; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; NONHUMAN; OSTEOMYELITIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ANALYSIS; URINARY TRACT INFECTION; URINE COLOR; URINE ODOR;

EID: 79953861127     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.01.017     Document Type: Short Survey

References (64)

1. Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant Gram-positive pathogens. Pharmacotherapy 2010;30:375-89.
2. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009;53:1271-4.
3. Llarrull LI, Fisher JF, Mobashery S. Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new β-lactams that meet the challenge. Antimicrob Agents Chemother 2009;53:4051-63.
4. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physiochemical and pharmacological properties. Bioorg Med Chem 2003;11:2427-37.
5. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA β-lactam antibiotics. J Am Chem Soc 2008;130:9212-3. (Pubitemid 352031115)
6. Iizawa Y, Nagai T, Ishikawa S, Hashiguchi S, Nakao M, Miyake A, et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004;10:146-56.
7. Jones R, Fritsche T, Ge Y, Kaniga K, Sader HS. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disk diffusion tests. J Antimicrob Chemother 2005;56:1047-52.
8. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-11.
9. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49:3501-12. (Pubitemid 41060605)
10. Corey R, Wilcox M, Talbot GH, Baculik T, Thye D. CANVAS-1: randomized, double-blinded, phase 3 study (P903-06) of the efficacy and safety of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSIs). In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2008 [Abstract L-1515a].
11. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009;53:4712-17.
12. Ishikawa T, Iizawa Y, Okonogi K, Miyake A. Studies on anti-MRSA parenteral cephalosporins. I. Synthesis and antibacterial activity of 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-hydroxyiminoacetamido] -3-(substituted imidazo[1,2-b]-pyridazinium-1-yl)methyl-3-cephem-4-carboxylates and related compounds. J Antibiot (Tokyo) 2000;53:1053-70.
13. Ishikawa T, Kamiyama K, Matsunaga N, Tawada H, Iizawa Y, Okonogi K, et al. Studies on anti-MRSA parenteral cephalosporins. II. Synthesis and antibacterial activity of 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)- alkoxyiminoacetamido]-3-(substituted imidazo[1,2-b]pyridazinium-1-yl)methyl-3- cephem-4-carboxylates and related compounds. J Antibiot (Tokyo) 2000;53:1071-85.
14. Ishikawa T, Kamiyama K, Nakayama Y, Iizawa Y, Okonogi K, Miyake A. Studies on anti-MRSA parenteral cephalosporins. III. Synthesis and antibacterial activity of 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)- alkoxyiminoacetamido]-3-[(E)-2-(1-alkylimidazo[1,2-b]pyridazinium-6-yl) thiovinyl]-3-cephem-4-carboxylates and related compounds. J Antibiot (Tokyo) 2001;54:257-77.
15. Ishikawa T, Nakayama Y, Tomimoto M, Niwa SI, Kamiyama K, Hashiguchi S, et al. Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parenteral administration. J Antibiot (Tokyo) 2001;54:364-74. (Pubitemid 32427935)
16. World Health Organization. International nonproprietary names for pharmaceutical substances (INN): list 59.WHODrug Information, vol. 22, no. 1. Geneva: WHO; 2008.
17. Forest Laboratories, Inc. Soluble dosage forms containing cephem derivatives suitable for parenteral administration. USPTO Patent Application 20090082326. http://www.frx.com [accessed 8 February 2011].
18. Patrick G. An introduction to medicinal chemistry. 3rd ed. Oxford, UK: Oxford University Press; 2005.
19. Page GP. Emerging cephalosporins. Expert Opin Emerg Drugs 2007;12:511-24.
20. Sauvage E, Kerff F, Terrak M, Ayala JA, Harlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev 2008;32:234-58. (Pubitemid 351257821)
21. Goffin C, Ghuysen JM. Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent. Microbiol Mol Biol Rev 2002;66:702-38. (Pubitemid 35425114)
22. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases. Antimicrob Agents Chemother 1998;42:1-17. (Pubitemid 28053319)
23. Koch AL. Bacterial wall as target for attack: past, present, and future research. Clin Microbiol Rev 2003;16:673-87. (Pubitemid 37296555)
24. Ben Zakour NL, Guinane CM, Fitzgerald JR. Pathogenomics of the staphylococci: insights into niche adaptation and the emergence of new virulent strains. FEMS Microbiol Lett 2008;289:1-12.
25. de Lencastre H, Oliveira D, Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr Opin Microbiol 2007;10:428-35. (Pubitemid 350052684)
26. Moisan HPM, Malouin F. Binding of ceftaroline (CPT) to penicillin-binding proteins (PBPs) of Streptococcus pneumoniae (SPN) and methicillin-resistant Staphylococcus aureus (MRSA). In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual meeting of the Infectious Diseases Society of America (IDSA). Washington, DC: ASM Press; 2008.
27. Clinical and Laboratory Standards Institute. http://www.clsi.org [accessed 8 February 2011].
28. Jacqueline C, Amador G, Caillon J, Mabecque VL, Batard E, Miègeville AF, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010;65:1749-52.
29. Ge Y, Maynard D, Rickert DE. Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection. Antimicrob Agents Chemother 2010;54:912-4.
30. Jacqueline C, Caillon J, Mabecque VL, Miègeville AF, Ge Y, Biek D, et al. In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob Agents Chemother 2009;53:5300-2.
31. Jacqueline C, Caillon J, Mabecque VL, Miègeville AF, Hamel A, Bugnon D, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007;51:3397-400.
32. Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:1153-5. (Pubitemid 351358404)
33. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52:3398-407.
34. Kurazono M, Ida T, Yamada K, Hirai Y, Maruyama T, Shitara E, et al. In vitro activities of ME1036 CP5609, a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2004;48:2831-7.
35. Sader H, Moet GJ, Fritsche TR, Jones RN. Evaluation of the bactericidal activity of the novel cephalosporin ceftaroline PPI-0903M, compared to ceftriaxone against Streptococcus pneumonia. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2006.
36. Shahid M, Sobia F, Singh A, Malik A, Khan HM, Jonas D, et al. β-Lactams and β-lactamase inhibitors in current- or potential-clinical practices: a comprehensive update. Crit Rev Microbiol 2009;35:81-108.
37. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009;33:515-9.
38. Livermore DM. β-Lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998;41:25-41. (Pubitemid 28284504)
39. Hinshaw RR, Schaadt RD, Murray B, Stapert D, Biek D, Ge Y, et al. Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual meeting of the Infectious Diseases Society of America (IDSA). Washington, DC: ASM Press; 2008.
40. Fuda C, Suvorov M, Vakulenko SB, Mobashery S. The basis for resistance to β-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J Biol Chem 2004;279:40802-6. (Pubitemid 39287677)
41. Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol Rev 2008;32:361-85.
42. Pinho MG, de Lencastre H, Tomasz A. An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc Natl Acad Sci U S A 2001;98:10886-91. (Pubitemid 32878714)
43. Fuda CS, Fisher JF, Mobashery S. β-Lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome. Cell Mol Life Sci 2005;62:2617-33. (Pubitemid 41721234)
44. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase- producing Enterobacteriaceae. J Antimicrob Chemother 2010;65:1428-32.
45. Ge Y, Floren L, Redman R, Liao S, Wilker MA. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subject. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2006 [Abstract no. A-1936].
46. Ge Y, Floren L, Redman R, Floren L, Liao S, Wikler MA. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subject receiving multiple dose intravenous infusion. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2006 [Abstract no. A-1937].
47. Riccobene T, Fang E, Thye D. A single and multiple dose study to determine the safety, tolerability and pharmacokinetics (PK) of ceftaroline (PPI-0903) administered by intramuscular injection to healthy subjects. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual meeting of the Infectious Diseases Society of America (IDSA). Washington, DC: ASM Press; 2008 [Abstract no. A-1936].
48. Ge Y, Liao S, Talbot GH. Population pharmacokinetic (PK) analysis of ceftaroline (PPI-0903) in volunteers and patients with complicated skin and skin structure infection. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2007 [Abstract no. A-34].
49. Jacqueline C, Caillon J, Miegeville A, Launay E, Batard E, Ge Y, et al. Penetration of ceftaroline, a new cephalosporin, in to lung tissue: measurement of plasma and lung tissue concentration after a short i.v infusion in rabbit. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2006 [Abstract no. A-1938].
50. Ge JY, Thye DA, Liao S, Talbot GH. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI). In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2006.
51. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006;50:1376-83.
52. Wilcox M, Corey GR, Talbot GH, Baculik T, Thye DA. CANVAS-2: randomized, double-blinded, phase 3 study (P903-07) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections. In: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2009.
53. Eckburg P, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA. FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2009.
54. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-6. (Pubitemid 47519351)
55. Ge JY, Nubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2006 [Abstract no. A-1937].
56. Riccobene T, Jakate A, Rank D, Thye DA. An open-label, pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis. In: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2009.
57. Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010;54:3027-30.
58. Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010;54:2716-9.
59. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51:641-50.
60. Eckburg P, Friedland D, Lee J, Llorens L, Critchley I, Thye D. FOCUS 1: randomized, double-blinded, multicenter phase 3 study of the efficacy and safety of ceftaroline vs ceftriaxone in community-acquired bacterial pneumonia. Am J Respir Crit Care Med 2010;181:A2273.
61. Jacobs MR, Good CE, Bajaksouzian S, Biek D, Critchley I. Serotypes and antimicrobial susceptibility of Streptococcus pneumoniae isolates from FOCUS 1 and 2. Two international trials of ceftaroline in patients hospitalized for community-acquired bacterial pneumonia. Am J Respir Crit Care Med 2010;181:A5482.
62. Sader HS, Williams G, Critchley I, Jones RN. Spectrum and activity of ceftaroline combined with NXL 104 tested against a challenge collection of pathogens with well characterized resistance. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2009 [Abstract no. F1-1492].
63. Castanheira M, Sader HS, Critchley I, William G, Jones RN. Bactericidal activity of ceftaroline combined with NXL 104 against critical targeted organisms possessing various resistance mechanisms. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2009 [Abstract no. F1-1493].
64. Forest Laboratories, Inc. Novexel's NXL104/ceftazidime combination commences phase II clinical trials in hospital patient with complicated urinary tract infections. Press release 2008. http://www.frx.com [accessed 8 February 2011].